Business Context and Reporting Period
Company: Lucid Diagnostics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 28, 2022
Reporting Period: Event-based report regarding a material definitive agreement entered into on March 28, 2022.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. It details a new financing facility and an immediate cash outflow:
- Equity Facility Size: Up to $50.0 million in common stock.
- Upfront Payment: $1,000,000 paid to CF Principal Investments LLC (Cantor) for the commitment.
- Share Cap: Maximum of 7,482,763 shares (19.99% of pre-agreement outstanding shares).
- Pricing Mechanism: 96% of the volume-weighted average price (VWAP) on the trading date of sale.
Material Changes
The primary material change is the establishment of a committed equity facility with CF Principal Investments LLC. This agreement allows the company to raise primary equity capital on a periodic basis at its sole discretion. The facility is structured similarly to an at-the-market offering but includes a committed buyer. The company paid a $1.0 million commitment fee upon execution.
Guidance, Outlook, and Risks
- Use of Proceeds: Expected to be used for working capital and general corporate purposes.
- Duration: The facility is available for 36 months following the effective date of the resale registration statement.
- Ownership Limits: Sales are restricted if the investor's beneficial ownership would exceed 4.99% of outstanding voting power.
- Termination: The company may terminate the agreement at any time after commencement with three trading days' prior written notice, at no cost or penalty.
- Regulatory Status: Shares are sold under Section 4(a)(2) exemption; a resale registration statement must be declared effective by the SEC before sales commence.
Investor Verification Checklist
- Verify the effective date of the Resale Registration Statement to determine when the facility becomes active.
- Monitor the company's stock price to assess the potential dilution impact given the 96% of VWAP pricing.
- Confirm whether the $1.0 million commitment fee has been reflected in the most recent cash balance updates.
- Check for any future filings indicating the actual utilization of the $50.0 million facility.
- Review the full text of the Common Stock Purchase Agreement (Exhibit 10.1) for specific conditions precedent to sales.